Vikas Somani

ORCID: 0000-0002-1640-0514
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bacillus and Francisella bacterial research
  • Bacterial Genetics and Biotechnology
  • Bacteriophages and microbial interactions
  • Immune cells in cancer
  • Pancreatic and Hepatic Oncology Research
  • Cancer Immunotherapy and Biomarkers
  • Escherichia coli research studies
  • Cancer Research and Treatments
  • Viral gastroenteritis research and epidemiology
  • Yersinia bacterium, plague, ectoparasites research
  • Brucella: diagnosis, epidemiology, treatment
  • Congenital Diaphragmatic Hernia Studies
  • Lipid Membrane Structure and Behavior
  • Cystic Fibrosis Research Advances
  • Caveolin-1 and cellular processes
  • Medical Imaging and Pathology Studies
  • Neuroendocrine Tumor Research Advances
  • Ferroptosis and cancer prognosis
  • Infections and bacterial resistance
  • Peptidase Inhibition and Analysis
  • 3D Printing in Biomedical Research
  • Hepatitis B Virus Studies
  • Salmonella and Campylobacter epidemiology
  • Pneumonia and Respiratory Infections
  • Bacterial biofilms and quorum sensing

Washington University in St. Louis
2020-2025

Jewish Hospital
2022

Barnes-Jewish Hospital
2022

Jawaharlal Nehru University
2015-2020

Milton Keynes Hospital
2013-2014

Milton Keynes Hospital NHS Foundation Trust
2013-2014

Abstract Targeting the mitogen-activated protein kinase (MAPK) cascade in pancreatic ductal adenocarcinoma (PDAC) remains clinically unsuccessful. We aim to develop a MAPK inhibitor-based therapeutic combination with strong preclinical efficacy. Utilizing reverse-phase array, we observe rapid phospho-activation of human epidermal growth factor receptor 2 (HER2) PDAC cells upon pharmacological inhibition. Mechanistically, inhibitors lead swift proteasomal degradation dual-specificity...

10.1038/s41467-024-46811-w article EN cc-by Nature Communications 2024-03-20

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with limited effectiveness to immune checkpoint therapies, primarily due its immunological “cold” tumor microenvironment (TME). We identified overactivation phosphorylated Transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1 a. k. MAP3K7) during development pancreatic cancer in Human and mouse PDAC models. demonstrated that phospho-TAK1 activity was increased human TMA tissues, it’s correlated high...

10.1158/1538-7445.am2025-3769 article EN Cancer Research 2025-04-21

Lipid rafts are dynamic, nanoscale assemblies of specific proteins and lipids, distributed heterogeneously on eukaryotic membrane. Flotillin-1, a conserved raft marker protein (RMP) harbor SPFH (Stomatin, Prohibitin, Flotillin, HflK/C) oligomerization domains to regulate various cellular processes through its interactions with other signaling or transport proteins. Rafts were thought be absent in prokaryotes hitherto, but recent report presence significance physiology Bacillus subtilis...

10.3389/fmicb.2016.00169 article EN cc-by Frontiers in Microbiology 2016-02-17

10.1016/j.ijmm.2015.06.001 article EN International Journal of Medical Microbiology 2015-06-19

Group A Streptococcus (GAS) infection causes a range of diseases, but vaccine development is hampered by the high number serotypes. Here, using reverse vaccinology authors identify SPy_2191 as cross-protective candidate. From 18 initially identified surface proteins, only conserved, surface-exposed and inhibits both GAS adhesion invasion. immunization in mice generates bactericidal antibodies resulting opsonophagocytic killing prevalent invasive serotypes different geographical regions,...

10.1038/s41467-020-17299-x article EN cc-by Nature Communications 2020-07-15

Currently used Brucella vaccines, abortus strain 19 and RB51, comprises of live attenuated strains prevent infection in animals. However, these vaccines pose potential risks to recipient animals such as attenuation reversal virulence susceptible hosts on administration. In this context, recombinant subunit emerge a safe competent alternative combating the disease. study, we formulated divalent vaccine consisting Omp25 L7/L12 B. evaluated individually well combination. Sera obtained from...

10.3390/pathogens9020152 article EN cc-by Pathogens 2020-02-24

Anthrax infection is primarily initiated by B. anthracis endospores that on entry into the host germinate to vegetative cells and cause severe bacteremia toxaemia employing an array of colonisation factors lethal tripartite toxin. The protective efficacy conventional antigen (PA) based anthrax vaccines improved co-administration with inactivated spores or its components. In present study, using structural vaccinology rationale we synthesized a bivalent protein r-PB encompassing toxin (PAIV)...

10.1038/s41598-018-25502-9 article EN cc-by Scientific Reports 2018-05-02

Thermophilic bacilli in both aerobic or facultative anaerobic forms have been isolated for over a hundred years from different mesophilic thermophilic environments as they are potential source of bioactive secondary metabolites. But the taxonomic resolution Bacillus genus at species strain level is very challenging insufficient divergence 16S rRNA genes. One such recurring problem among anthracis, B. cereus and thuringiensis. The disease-causing anthracis strains their characteristic...

10.2174/1389202920666191203121610 article EN Current Genomics 2019-12-04

Anthrax vaccines primarily relying only on protective antigen (PA), the cell binding component in anthrax toxins provide incomplete protection when challenged with spores of virulent encapsulated Bacillus anthracis strains. Alternatively, formaldehyde inactivated (FIS) or recombinant spore components generate anti-spore immune responses that inhibit early stages infection and augment PA efficacy. In present study domain IV was spliced exosporium BxpB via a flexible G4S linker to single...

10.3389/fimmu.2019.00498 article EN cc-by Frontiers in Immunology 2019-03-19

Pulmonary Alveolar Proteinosis (PAP) is a rare condition with an incidence of one in two million and classified as primary or secondary. This the first reported case presenting slow resolving pneumonia.

10.1016/j.rmcr.2013.06.001 article EN cc-by-nc-nd Respiratory Medicine Case Reports 2013-01-01

<h3>Background</h3> Infiltration of myeloid-derived suppressor cells (MDSCs) establishes an immune-suppressive tumor microenvironment (TME) in Pancreatic Ductal Adenocarcinoma (PDAC), exacerbated by chronic inflammation and recurrent gemcitabine (GEM) mediated chemotherapy. Consequently, developing immune-modulatory pro-drug form GEM, targeting modulating the suppressive TME &amp; TAMs, holds promise for preventing cancer recurrence increasing survival rates. <h3>Methods</h3> To develop...

10.1136/jitc-2024-sitc2024.1447 article EN cc-by-nc Regular and Young Investigator Award Abstracts 2024-11-01

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and treatment-refractory malignancies. The lack an effective screening tool results in majority patients being diagnosed at late stages, which underscores urgent need to develop more sensitive specific imaging modalities, particularly detecting occult metastases, aid clinical decision-making. tumor microenvironment PDAC heavily infiltrated with myeloid-derived suppressor cells (MDSCs) that express C–C chemokine receptor...

10.1021/acsptsci.3c00303 article EN ACS Pharmacology & Translational Science 2023-12-05

Abstract Background Bacillus anthracis (BA), the etiological agent of anthrax, secretes protective antigen (PA), lethal factor (LF), and edema (EF) as major virulence factors. Among them, PA based vaccines are most indispensable for providing immunity against BA, but low shelf life limits its reliability. Previous studies revealed that domain IV includes B-cell epitopes designated ID I, II, III; among II III have been found to possess more toxin neutralization activity produce high antibody...

10.1093/ofid/ofx163.717 article EN cc-by-nc-nd Open Forum Infectious Diseases 2017-01-01

Abstract Effective immunotherapy in pancreatic ductal adenocarcinoma (PDAC) is impeded by multiple barriers the tumor microenvironment. These include dense extracellular matrix (ECM), excessive inhibitory myeloid cells, cytokines and chemokines, which collectively incapacitate anti-tumour T cells. Constitutive activation NF-kB pathway a mechanism that drives intrinsic survival of PDAC cells stromal fibrosis, but its impact on immunity has not been investigated. Using The Cancer Genome Atlas...

10.1158/1538-7445.panca20-po-017 article EN Cancer Research 2020-11-13
Coming Soon ...